• Explore /
  • Poster
  • / Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Abstract Video & Slides Poster

Authors

Katy Beckermann

Katy Beckermann

Vanderbilt-Ingram Cancer Center, Nashville, TN

Katy Beckermann , Matthew T Campbell , Naomi B. Haas , Moshe Chaim Ornstein , Xin Gao , Shifeng S. Mao , Hans J. Hammers , Saby George , Ariel Ann Nelson , Theodore Stewart Gourdin , Holavanahalli Keshava-Prasad , Arif Hussain , Christopher J. Hoimes , Hongxia Yan , Vanessa Esquibel , Gail McIntyre , Robert B. Geller , Martin H Voss , Brian I. Rini , Neil J. Shah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT04300140

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4534)

DOI

10.1200/JCO.2023.41.16_suppl.4534

Abstract #

4534

Poster Bd #

26

Abstract Disclosures

Similar Posters

First Author: Katy Beckermann

First Author: Neil J. Shah

First Author: Neil J. Shah

First Author: Michael B. Atkins